Literature DB >> 15578262

Limited impact of multiple 5' single-nucleotide polymorphisms on the transcriptional control of the human beta 2-adrenoceptor gene.

Robert Westland1, Anneke van Veen, Henk M Jansen, Rene E Jonkers, Eddy A Wierenga.   

Abstract

The human beta(2)-adrenoceptor (beta(2)-AR) is subject to agonist-induced down-regulation. The degree of down-regulation is associated with certain single-nucleotide polymorphisms (SNPs) through yet unknown mechanisms. The 5'-leader sequence of the beta(2)-AR gene contains several SNPs that are in strong linkage disequilibrium. The -367 T/C polymorphism, in particular, has been shown to affect transcriptional activity in reporter gene assays. In the present study we analysed the impact of this -367 SNP on the transcription rate of the beta(2)-AR gene in the context of the complete natural locus. Taking advantage of the additional full disequilibrium with the +79 SNP in the beta(2)-AR coding sequence, allele-specific transcript quantification was performed in PBMCs of six -367 heterozygous mild asthmatic patients. Our data are in line with the reported impact of the -367 SNP and give no indication of additional haplotype-related effects on beta(2)-AR transcription. We further show that the -367 SNP affects the binding of a yet unidentified transcription factor complex, whose binding activity is not modulated by pharmacological compounds that induce or down-regulate beta(2)-AR expression, suggesting a role in constitutive steady state expression rather than in inducible expression. As the beta(2)-AR allele with a higher transcription rate associates with stronger agonist-induced down-regulation, it is not likely that the -367 SNP is causally related to the degree of down-regulation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15578262     DOI: 10.1007/s00251-004-0732-8

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  20 in total

1.  Identification of novel polymorphisms within the promoter region of the human beta2 adrenergic receptor gene.

Authors:  M G Scott; C Swan; A P Wheatley; I P Hall
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

2.  Lack of IL-12 signaling in human allergen-specific Th2 cells.

Authors:  C M Hilkens; G Messer; K Tesselaar; A G van Rietschoten; M L Kapsenberg; E A Wierenga
Journal:  J Immunol       Date:  1996-11-15       Impact factor: 5.422

3.  Delineation of the intronless nature of the genes for the human and hamster beta 2-adrenergic receptor and their putative promoter regions.

Authors:  B K Kobilka; T Frielle; H G Dohlman; M A Bolanowski; R A Dixon; P Keller; M G Caron; R J Lefkowitz
Journal:  J Biol Chem       Date:  1987-05-25       Impact factor: 5.157

4.  cDNA for the human beta 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor.

Authors:  B K Kobilka; R A Dixon; T Frielle; H G Dohlman; M A Bolanowski; I S Sigal; T L Yang-Feng; U Francke; M G Caron; R J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

Review 5.  Beta-adrenergic receptors and their regulation.

Authors:  P J Barnes
Journal:  Am J Respir Crit Care Med       Date:  1995-09       Impact factor: 21.405

6.  Effect of short- and long-acting beta 2-adrenoceptor agonists on pulmonary beta 2-adrenoceptor expression in human lung.

Authors:  M Nishikawa; J C Mak; P J Barnes
Journal:  Eur J Pharmacol       Date:  1996-12-27       Impact factor: 4.432

7.  An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta 2-agonist.

Authors:  D H Yates; S A Kharitonov; P J Barnes
Journal:  Am J Respir Crit Care Med       Date:  1996-12       Impact factor: 21.405

8.  Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells.

Authors:  S A Green; J Turki; P Bejarano; I P Hall; S B Liggett
Journal:  Am J Respir Cell Mol Biol       Date:  1995-07       Impact factor: 6.914

9.  Polymorphisms of the 5' leader cistron of the human beta2-adrenergic receptor regulate receptor expression.

Authors:  D W McGraw; S L Forbes; L A Kramer; S B Liggett
Journal:  J Clin Invest       Date:  1998-12-01       Impact factor: 14.808

10.  Rapid onset of tolerance to the bronchoprotective effect of salmeterol.

Authors:  R Bhagat; S Kalra; V A Swystun; D W Cockcroft
Journal:  Chest       Date:  1995-11       Impact factor: 9.410

View more
  6 in total

Review 1.  Understanding genomics: implications for the emergency medicine physician and the treatment of asthma.

Authors:  Robert J Freishtat; Stephen J Teach
Journal:  Pediatr Emerg Care       Date:  2006-01       Impact factor: 1.454

2.  Allele-specific binding of airway nuclear extracts to polymorphic beta2-adrenergic receptor 5' sequence.

Authors:  Alfredo Panebra; Mary Rose Schwarb; Clare B Glinka; Stephen B Liggett
Journal:  Am J Respir Cell Mol Biol       Date:  2007-01-25       Impact factor: 6.914

3.  Role of ADRB2 gene polymorphism in asthma and response to beta(2)-agonists in Polish children.

Authors:  A Szczepankiewicz; A Breborowicz; P Sobkowiak; L Kramer; A Popiel
Journal:  J Appl Genet       Date:  2009       Impact factor: 3.240

4.  Influence of beta2-adrenoceptor gene polymorphisms on beta2-adrenoceptor-mediated responses in human lung mast cells.

Authors:  L J Kay; A Rostami-Hodjegan; S K Suvarna; P T Peachell
Journal:  Br J Pharmacol       Date:  2007-07-23       Impact factor: 8.739

5.  Limited beta2-adrenoceptor haplotypes display different agonist mediated airway responses in asthmatics.

Authors:  Anneke van Veen; Eddy A Wierenga; Robert Westland; Frank R Weller; Guus A M Hart; Henk M Jansen; René E Jonkers
Journal:  Respir Res       Date:  2006-01-31

6.  Beta2 adrenergic receptor (ADRβ2) haplotype pair (2/4) is associated with severe asthma.

Authors:  Li Ping Chung; Svetlana Baltic; Manuel Ferreira; Suzanna Temple; Grant Waterer; Philip J Thompson
Journal:  PLoS One       Date:  2014-04-01       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.